ArticleBioinformatics (Oxford, England)2026
Joint representation learning for oncology applications.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationThe integration of tumour imaging data and molecular sequencing information can advance our understanding of cancer biology by combining complementary perspectives of tumour phenotype and genotype. However, integrating multi-modal data across heterogeneous and high-dimensional data domains remains a significant computational challenge.
resultsHere, we introduce an unsupervised manifold alignment approach for real-world data integration based on Joint Multidimensional Scaling (Joint MDS) and extend it to a three-modality framework (Joint MDS3). We apply this method to integrate radiomic features from magnetic resonance imaging (MRI) with transcriptomic, epigenomic, and copy number variation (CNV) data from patients with glioblastoma multiforme (GBM) and lower-grade gliomas (LGG). Compared to baselines such as Pamona and single-cell optimal transport (SCOTv2), Joint MDS consistently outperforms baseline Pamona in cases and achieves competitive performance relative to baseline SCOTv2, outperforming its fraction of samples closer to an incorrect match (FOSCTTM) in four out of six cases. Joint MDS attains an average label transfer accuracy of 74.8%, approximately 4% higher than that of Pamona and SCOTv2, and reduces FOSCTTM to 51% or less across real-world datasets. We further demonstrate our extension JointMDS3 on both synthetic and real-world examples. Our results highlight the potential of Joint MDS to enhance the integration of diverse data types into a unified representation, ultimately advancing computational approaches in complex diseases. AVAILABILITY AND IMPLEMENTATION: The implementation of our work is available at gitlab.ethz.ch/BMDSlab/publications/oncology/joint-representation-learning-for-oncology-applications and archived at doi.org/10.5281/zenodo.17219404.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.